PMV Pharmaceuticals GAAP EPS of -$1.48 beats by $0.06
at seekingalpha.com (Fri, 6-Mar 2:06 PM)
NEJM Publication of PMV Pharma’s Rezatapopt Data Highlights 46% Response Rate in Ovarian Cancer—What’s Next for TP53 Y220C-Mutated Tumors?
Market Chameleon (Fri, 27-Feb 10:37 AM)
NEJM Spotlights PMV Pharma's Rezatapopt: 46% Response Rate in Ovarian Cancer with TP53 Y220C Mutation
Market Chameleon (Thu, 26-Feb 11:26 AM)
